Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 21:45 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2 / Phase 3CompletedINTERVENTIONAL

Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment

ClinicalTrials.gov · NCT02946684 · Registry updated: 2019-07-08

Condition / research focus: Infertility
Sponsor: Sven O. Skouby
Countries with listed sites: Denmark
Registry dates and results: Start: 2017-02-01. Completion: 2018-10-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Letrozole (drug) — also listed as: Aromatase Inhibitor
Placebo (drug) — also listed as: Lactose Monohydrate

Where the study takes place — 4 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Unit of Reproductive Medicine, Herlev Hospital
Herlev, Capital Region, Denmark
Site recruitment: Not reported
Department of Fertility, Juliane Marie Centeret
Copenhagen, Capitol Region, Denmark
Site recruitment: Not reported
Clinic of Fertility, Hvidovre Hospital
Hvidovre, Capitol Region, Denmark
Site recruitment: Not reported
Clinic of Fertility, Holbæk Hospital
Holbæk, Region of Zealand, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study

ClinicalTrials.gov · NCT03447184 · Registry updated: 2019-07-05

Condition / research focus: Poor Ovarian Response
Sponsor: Mỹ Đức Hospital
Countries with listed sites: Vietnam
Registry dates and results: Start: 2018-03-26. Completion: 2019-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Androgen priming (drug) — also listed as: low dose hCG and aromatase inhibitor priming

Where the study takes place — 1 listed sites

Lan N Vuong
Ho Chi Minh City, Vietnam
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles

ClinicalTrials.gov · NCT04008966 · Registry updated: 2019-07-05

Condition / research focus: Assisted Reproduction
Sponsor: Cairo University
Countries with listed sites: Egypt
Registry dates and results: Start: 2016-07-20. Completion: 2019-07-01 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

combined oral contaraceptive pills (drug) — also listed as: Gynera
recombinant FSH (drug)
Urinaru gonadotropin (drug)
GnRH antagonist (drug) — also listed as: Cetrotide
Human chorionic gonadotropin (drug)
GnRH agonist (drug) — also listed as: triptorelin
Ovum pick up (procedure)
Embryo transfer (procedure)
natural Progesterone (drug) — also listed as: Prontogest

Where the study takes place — 1 listed sites

Kasr Alainy medical school
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation

ClinicalTrials.gov · NCT02449889 · Registry updated: 2019-06-26

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Brazil
Registry dates and results: Start: 2016-04. Completion: 2018-03-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

highly purified human chorionic gonadotropin (drug) — also listed as: CHORAPUR, BREVACTID
recombinant human chorionic gonadotropin (drug) — also listed as: OVIDREL, OVITRELLE

Where the study takes place — 1 listed sites

Instituto Ideia Fértil de Saúde Reproductive (there may be other sites in this country)
São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Study of Dual Trigger Ovulation in Oocyte Donors

ClinicalTrials.gov · NCT01443546 · Registry updated: 2019-06-26

Condition / research focus: Infertility
Sponsor: Weill Medical College of Cornell University
Countries with listed sites: United States
Registry dates and results: Start: 2013-01. Completion: 2016-06 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HCG (drug)
Lupron Trigger (drug)
Dual Trigger (drug)

Where the study takes place — 1 listed sites

Weill Cornell Medical College- Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

Randomized CO2 vs Sham Laser Treatment of Provoked Vestibulodynia

ClinicalTrials.gov · NCT03390049 · Registry updated: 2019-06-10

Condition / research focus: Vestibulodynia
Sponsor: Wake Forest University Health Sciences
Countries with listed sites: United States
Registry dates and results: Start: 2018-08. Completion: 2019-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fractional CO2 Laser Treatment (device) — also listed as: Fractional microablative CO2 laser system
Sham Laser Treatment (device) — also listed as: Fractional microablative CO2 laser system

Where the study takes place — 1 listed sites

Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Medical Abortion Self-Confirmation (MASC)

ClinicalTrials.gov · NCT03148587 · Registry updated: 2019-06-07

Condition / research focus: Medical Abortion
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2017-05-01. Completion: 2018-05-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Self-assessment: MLPT (behavioral)
Self-assessment: LSPT (behavioral)

Where the study takes place — 1 listed sites

Stanford Health Care
Stanford, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Impact of Vaginal Intercourse on Pregnancy Rates After Frozen Embryo Transfer

ClinicalTrials.gov · NCT03974295 · Registry updated: 2019-06-04

Condition / research focus: Infertility; Pregnancy Related; IVF
Sponsor: University of South Florida
Countries with listed sites: No country reported
Registry dates and results: Start: 2019-07-01. Completion: 2022-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Vaginal unprotected intercourse (behavioral)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients

ClinicalTrials.gov · NCT03954197 · Registry updated: 2019-05-20

Condition / research focus: Fertility Preservation; Breast Cancer
Sponsor: Hôpital Jean Verdier
Countries with listed sites: France
Registry dates and results: Start: 2014-09-09. Completion: 2019-10-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

No hormone (other)
hCG (other)
GnRH a (other)

Where the study takes place — 1 listed sites

Hôpital Jean Verdier
Bondy, France
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1 / Phase 2TerminatedINTERVENTIONAL

Positron Emission Tomography (PET) Imaging Studies With NIS Reporter

ClinicalTrials.gov · NCT02907073 · Registry updated: 2019-05-17

Condition / research focus: Myeloma; Endometrial Cancer
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2016-09. Completion: 2017-12 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

BF4 (drug) — also listed as: Tetrafluoroborate, TFB

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)

ClinicalTrials.gov · NCT01154192 · Registry updated: 2019-04-30

Condition / research focus: PCOS
Sponsor: University of California, San Diego
Countries with listed sites: United States
Registry dates and results: Start: 2011-08. Completion: 2014-09 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dexamethasone (drug) — also listed as: recombinant human chorionic gonadotropin (r-hCG)
recombinant human chorionic gonadotropin (r-hCG) (drug) — also listed as: Ovidrel

Where the study takes place — 1 listed sites

UCSD School of Medicine
La Jolla, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

CAPA-IVM Versus STANDARD IVM

ClinicalTrials.gov · NCT03921710 · Registry updated: 2019-04-23

Condition / research focus: Infertility, Female
Sponsor: Mỹ Đức Hospital
Countries with listed sites: Vietnam
Registry dates and results: Start: 2017-04-29. Completion: 2018-10-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CAPA-IVM (drug)
Standard-IVM (drug)

Where the study takes place — 1 listed sites

My Duc Hospital
Ho Chi Minh City, Vietnam
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Timing and Intrauterine Insemination in Unexplained Infertility

ClinicalTrials.gov · NCT03920514 · Registry updated: 2019-04-19

Condition / research focus: Intrauterine Insemination
Sponsor: Sohag University
Countries with listed sites: No country reported
Registry dates and results: Start: 2019-04-30. Completion: 2019-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

hCG (drug) — also listed as: Pregnyl

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Value of Myomectomy in Women With Intramural Myoma Before IVF.

ClinicalTrials.gov · NCT03904368 · Registry updated: 2019-04-05

Condition / research focus: Fibroid Uterus; IVF
Sponsor: Cairo University
Countries with listed sites: Egypt
Registry dates and results: Start: 2019-04. Completion: 2020-12 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Open myomectomy (procedure)
Gonadotropins (drug) — also listed as: Controlled Ovarian stimulation
Human chorionic gonadotropin (drug) — also listed as: Ovulation triggering
Ovum pick up (procedure)
Embryo transfer (procedure)

Where the study takes place — 1 listed sites

Kasr Alainy medical school
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Evaluation of the Axonemal Dynein Heavy Chain 5 and Creatine Kinase Concentration in Cervical Fluid for Early Detection of the Ectopic Pregnancy

ClinicalTrials.gov · NCT02995356 · Registry updated: 2019-03-28

Condition / research focus: Ectopic Pregnancy
Sponsor: Ege University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2016-09. Completion: 2018-11 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Collecting cervical liquid and sera samples (other)

Where the study takes place — 1 listed sites

Ege University, Medicine Faculty, Department of Obstetrics and Gynecology
Izmir, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Effect of Vitamin D on Fertility

ClinicalTrials.gov · NCT03890458 · Registry updated: 2019-03-26

Condition / research focus: Infertility; Infertility, Female; Vitamin D Deficiency; Vitamin D3 Deficiency
Sponsor: Akdeniz University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2017-05-01. Completion: 2017-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

DEVIT-3 (drug)

Where the study takes place — 1 listed sites

Murat Özekinci
Antalya, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Triggering of Follicular Maturation

ClinicalTrials.gov · NCT02916173 · Registry updated: 2019-03-20

Condition / research focus: Increase Pregnancy Rate
Sponsor: Assiut University
Countries with listed sites: Egypt
Registry dates and results: Start: 2016-11. Completion: 2019-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant Human Chorionic Gonadotrophin (drug) — also listed as: Ovitrelle
human chorionic gonadotrophin + gonadotrophin releasing hormone agonist (drug)

Where the study takes place — 1 listed sites

Ahmed Abbas
Assiut, Cairo Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization

ClinicalTrials.gov · NCT02865681 · Registry updated: 2019-03-19

Condition / research focus: Infertility
Sponsor: New Hope Fertility Center
Countries with listed sites: United States
Registry dates and results: Start: 2016-07-01. Completion: 2017-06-07 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Menopur (drug) — also listed as: gonadotropin
Synarel (drug) — also listed as: GnRH agonist
HCG trigger (drug) — also listed as: HCG
Clomiphene citrate (drug) — also listed as: Clomid
Letrozole (drug) — also listed as: Femara

Where the study takes place — 1 listed sites

New Hope Fertility Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

ClinicalTrials.gov · NCT00807599 · Registry updated: 2019-03-15

Condition / research focus: Multiple Myeloma
Sponsor: Memorial Sloan Kettering Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2008-12-10. Completion: 2018-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Stem cell transplant x 1 or x 2 (procedure) — also listed as: In the initial 4 cycles of therapy, pts will receive oral lenalidomide at the, starting dose of 25mg on days 1-21 every 28 days (1 cycle) with dose, adjustments for creatinine clearance (CRCL) & dose reductions for toxicity., Pts will receive low-dose oral dexamethasone at 40mg weekly on days 1, 8, 15 &, 22 of each 28-day cycle with dose reductions as below for toxicity (the weekly, dose could be split over 2 days in the week i.e. 20mg on days 1, 4, 8, 11, 15,, 18, 22, & 25 for better tolerance). For SCT, pts are adm to hosp. High-dose, melphalan is admin in a single dose on day -2 or split dose on days -3 & -2,, through a cvc. Melphalan doseadjustments are made for age & CRCL,. Pts with, CRCL,> 51ml/min receive melphalan at 200mg/m2. Pts with CRCL < 51ml/min, (to be evaluated within 2 weeks of SCT) will receive 140mg/m2. Pts > 70 years, old receive 140mg/m2 also. Each SCT in a tandem SCT is a clinically discrete, event & these rules of dose adjustment apply to each SCT. It is possible,, that pts will get different doses of melphalan in tandem SCT
lenalidomide and dexamethasone (drug) — also listed as: In the initial 4 cycles of therapy, pts will receive oral lenalidomide at the, starting dose of 25mg on days 1-21 every 28 days (one cycle) with dose, adjustments for creatinine clearance and dose reductions. Pts will receive, low-dose oral dexamethasone at 40mg weekly on days 1, 8, 15 & 22 of each, 28-day cycle with dose reductions (the weekly dose could be split over 2 days, in the week i.e. 20mg on days 1, 4, 8, 11, 15, 18, 22, & 25 for better, tolerance). For continued Ld, pts will resume Ld at the last dose tolerated, during the initial 4 cycles, with prophylactics & dose reductions as indicated., Lenalidomide will be continued until progression of disease, if as tolerated., Low-dose dexamethasone will be continued for 1 year (from the start of initial, treatment), as tolerated. Dose adjustments will follow guidelines. Pts will, be seen every 3 months by their physician & their disease will be reassessed., Pts will also have a CBC & pregnancy test performed monthly.

Where the study takes place — 7 listed sites

Memoral Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
Site recruitment: Not reported
Memorial Sloan-Kettering Cancer Center @ Suffolk
Commack, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering West Harrison
Harrison, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States
Site recruitment: Not reported
Memoral Sloan Kettering Cancer Center at Phelps
Sleepy Hollow, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center
Sleepy Hollow, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Success Rate Natural Cycles Versus Modified Natural Cycles in Frozen Embryos

ClinicalTrials.gov · NCT03798886 · Registry updated: 2019-03-13

Condition / research focus: Infertility, Female
Sponsor: Acibadem University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2018-01-01. Completion: 2019-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

natural cycle (other) — also listed as: natural LH surge
modified natural cycle (other) — also listed as: recombinant hcg
embryo transfer (other) — also listed as: frozen embryo transfer

Where the study takes place — 1 listed sites

Acibadem MAA University Atakent Hospital
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 21:45 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2 / Phase 3CompletedINTERVENTIONAL

Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment

ClinicalTrials.gov · NCT02946684 · Registry updated: 2019-07-08

Condition / research focus: Infertility
Sponsor: Sven O. Skouby
Countries with listed sites: Denmark
Registry dates and results: Start: 2017-02-01. Completion: 2018-10-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Letrozole (drug) — also listed as: Aromatase Inhibitor
Placebo (drug) — also listed as: Lactose Monohydrate

Where the study takes place — 4 listed sites

Unit of Reproductive Medicine, Herlev Hospital
Herlev, Capital Region, Denmark
Site recruitment: Not reported
Department of Fertility, Juliane Marie Centeret
Copenhagen, Capitol Region, Denmark
Site recruitment: Not reported
Clinic of Fertility, Hvidovre Hospital
Hvidovre, Capitol Region, Denmark
Site recruitment: Not reported
Clinic of Fertility, Holbæk Hospital
Holbæk, Region of Zealand, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study

ClinicalTrials.gov · NCT03447184 · Registry updated: 2019-07-05

Condition / research focus: Poor Ovarian Response
Sponsor: Mỹ Đức Hospital
Countries with listed sites: Vietnam
Registry dates and results: Start: 2018-03-26. Completion: 2019-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Androgen priming (drug) — also listed as: low dose hCG and aromatase inhibitor priming

Where the study takes place — 1 listed sites

Lan N Vuong
Ho Chi Minh City, Vietnam
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles

ClinicalTrials.gov · NCT04008966 · Registry updated: 2019-07-05

Condition / research focus: Assisted Reproduction
Sponsor: Cairo University
Countries with listed sites: Egypt
Registry dates and results: Start: 2016-07-20. Completion: 2019-07-01 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

combined oral contaraceptive pills (drug) — also listed as: Gynera
recombinant FSH (drug)
Urinaru gonadotropin (drug)
GnRH antagonist (drug) — also listed as: Cetrotide
Human chorionic gonadotropin (drug)
GnRH agonist (drug) — also listed as: triptorelin
Ovum pick up (procedure)
Embryo transfer (procedure)
natural Progesterone (drug) — also listed as: Prontogest

Where the study takes place — 1 listed sites

Kasr Alainy medical school
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation

ClinicalTrials.gov · NCT02449889 · Registry updated: 2019-06-26

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Brazil
Registry dates and results: Start: 2016-04. Completion: 2018-03-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

highly purified human chorionic gonadotropin (drug) — also listed as: CHORAPUR, BREVACTID
recombinant human chorionic gonadotropin (drug) — also listed as: OVIDREL, OVITRELLE

Where the study takes place — 1 listed sites

Instituto Ideia Fértil de Saúde Reproductive (there may be other sites in this country)
São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Study of Dual Trigger Ovulation in Oocyte Donors

ClinicalTrials.gov · NCT01443546 · Registry updated: 2019-06-26

Condition / research focus: Infertility
Sponsor: Weill Medical College of Cornell University
Countries with listed sites: United States
Registry dates and results: Start: 2013-01. Completion: 2016-06 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HCG (drug)
Lupron Trigger (drug)
Dual Trigger (drug)

Where the study takes place — 1 listed sites

Weill Cornell Medical College- Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

Randomized CO2 vs Sham Laser Treatment of Provoked Vestibulodynia

ClinicalTrials.gov · NCT03390049 · Registry updated: 2019-06-10

Condition / research focus: Vestibulodynia
Sponsor: Wake Forest University Health Sciences
Countries with listed sites: United States
Registry dates and results: Start: 2018-08. Completion: 2019-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Fractional CO2 Laser Treatment (device) — also listed as: Fractional microablative CO2 laser system
Sham Laser Treatment (device) — also listed as: Fractional microablative CO2 laser system

Where the study takes place — 1 listed sites

Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Medical Abortion Self-Confirmation (MASC)

ClinicalTrials.gov · NCT03148587 · Registry updated: 2019-06-07

Condition / research focus: Medical Abortion
Sponsor: Stanford University
Countries with listed sites: United States
Registry dates and results: Start: 2017-05-01. Completion: 2018-05-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Self-assessment: MLPT (behavioral)
Self-assessment: LSPT (behavioral)

Where the study takes place — 1 listed sites

Stanford Health Care
Stanford, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Impact of Vaginal Intercourse on Pregnancy Rates After Frozen Embryo Transfer

ClinicalTrials.gov · NCT03974295 · Registry updated: 2019-06-04

Condition / research focus: Infertility; Pregnancy Related; IVF
Sponsor: University of South Florida
Countries with listed sites: No country reported
Registry dates and results: Start: 2019-07-01. Completion: 2022-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Vaginal unprotected intercourse (behavioral)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients

ClinicalTrials.gov · NCT03954197 · Registry updated: 2019-05-20

Condition / research focus: Fertility Preservation; Breast Cancer
Sponsor: Hôpital Jean Verdier
Countries with listed sites: France
Registry dates and results: Start: 2014-09-09. Completion: 2019-10-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

No hormone (other)
hCG (other)
GnRH a (other)

Where the study takes place — 1 listed sites

Hôpital Jean Verdier
Bondy, France
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1 / Phase 2TerminatedINTERVENTIONAL

Positron Emission Tomography (PET) Imaging Studies With NIS Reporter

ClinicalTrials.gov · NCT02907073 · Registry updated: 2019-05-17

Condition / research focus: Myeloma; Endometrial Cancer
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2016-09. Completion: 2017-12 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

BF4 (drug) — also listed as: Tetrafluoroborate, TFB

Where the study takes place — 1 listed sites

Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)

ClinicalTrials.gov · NCT01154192 · Registry updated: 2019-04-30

Condition / research focus: PCOS
Sponsor: University of California, San Diego
Countries with listed sites: United States
Registry dates and results: Start: 2011-08. Completion: 2014-09 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dexamethasone (drug) — also listed as: recombinant human chorionic gonadotropin (r-hCG)
recombinant human chorionic gonadotropin (r-hCG) (drug) — also listed as: Ovidrel

Where the study takes place — 1 listed sites

UCSD School of Medicine
La Jolla, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

CAPA-IVM Versus STANDARD IVM

ClinicalTrials.gov · NCT03921710 · Registry updated: 2019-04-23

Condition / research focus: Infertility, Female
Sponsor: Mỹ Đức Hospital
Countries with listed sites: Vietnam
Registry dates and results: Start: 2017-04-29. Completion: 2018-10-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CAPA-IVM (drug)
Standard-IVM (drug)

Where the study takes place — 1 listed sites

My Duc Hospital
Ho Chi Minh City, Vietnam
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Timing and Intrauterine Insemination in Unexplained Infertility

ClinicalTrials.gov · NCT03920514 · Registry updated: 2019-04-19

Condition / research focus: Intrauterine Insemination
Sponsor: Sohag University
Countries with listed sites: No country reported
Registry dates and results: Start: 2019-04-30. Completion: 2019-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

hCG (drug) — also listed as: Pregnyl

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Value of Myomectomy in Women With Intramural Myoma Before IVF.

ClinicalTrials.gov · NCT03904368 · Registry updated: 2019-04-05

Condition / research focus: Fibroid Uterus; IVF
Sponsor: Cairo University
Countries with listed sites: Egypt
Registry dates and results: Start: 2019-04. Completion: 2020-12 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Open myomectomy (procedure)
Gonadotropins (drug) — also listed as: Controlled Ovarian stimulation
Human chorionic gonadotropin (drug) — also listed as: Ovulation triggering
Ovum pick up (procedure)
Embryo transfer (procedure)

Where the study takes place — 1 listed sites

Kasr Alainy medical school
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Evaluation of the Axonemal Dynein Heavy Chain 5 and Creatine Kinase Concentration in Cervical Fluid for Early Detection of the Ectopic Pregnancy

ClinicalTrials.gov · NCT02995356 · Registry updated: 2019-03-28

Condition / research focus: Ectopic Pregnancy
Sponsor: Ege University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2016-09. Completion: 2018-11 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Collecting cervical liquid and sera samples (other)

Where the study takes place — 1 listed sites

Ege University, Medicine Faculty, Department of Obstetrics and Gynecology
Izmir, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Effect of Vitamin D on Fertility

ClinicalTrials.gov · NCT03890458 · Registry updated: 2019-03-26

Condition / research focus: Infertility; Infertility, Female; Vitamin D Deficiency; Vitamin D3 Deficiency
Sponsor: Akdeniz University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2017-05-01. Completion: 2017-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

DEVIT-3 (drug)

Where the study takes place — 1 listed sites

Murat Özekinci
Antalya, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Triggering of Follicular Maturation

ClinicalTrials.gov · NCT02916173 · Registry updated: 2019-03-20

Condition / research focus: Increase Pregnancy Rate
Sponsor: Assiut University
Countries with listed sites: Egypt
Registry dates and results: Start: 2016-11. Completion: 2019-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant Human Chorionic Gonadotrophin (drug) — also listed as: Ovitrelle
human chorionic gonadotrophin + gonadotrophin releasing hormone agonist (drug)

Where the study takes place — 1 listed sites

Ahmed Abbas
Assiut, Cairo Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization

ClinicalTrials.gov · NCT02865681 · Registry updated: 2019-03-19

Condition / research focus: Infertility
Sponsor: New Hope Fertility Center
Countries with listed sites: United States
Registry dates and results: Start: 2016-07-01. Completion: 2017-06-07 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Menopur (drug) — also listed as: gonadotropin
Synarel (drug) — also listed as: GnRH agonist
HCG trigger (drug) — also listed as: HCG
Clomiphene citrate (drug) — also listed as: Clomid
Letrozole (drug) — also listed as: Femara

Where the study takes place — 1 listed sites

New Hope Fertility Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

ClinicalTrials.gov · NCT00807599 · Registry updated: 2019-03-15

Condition / research focus: Multiple Myeloma
Sponsor: Memorial Sloan Kettering Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2008-12-10. Completion: 2018-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Stem cell transplant x 1 or x 2 (procedure) — also listed as: In the initial 4 cycles of therapy, pts will receive oral lenalidomide at the, starting dose of 25mg on days 1-21 every 28 days (1 cycle) with dose, adjustments for creatinine clearance (CRCL) & dose reductions for toxicity., Pts will receive low-dose oral dexamethasone at 40mg weekly on days 1, 8, 15 &, 22 of each 28-day cycle with dose reductions as below for toxicity (the weekly, dose could be split over 2 days in the week i.e. 20mg on days 1, 4, 8, 11, 15,, 18, 22, & 25 for better tolerance). For SCT, pts are adm to hosp. High-dose, melphalan is admin in a single dose on day -2 or split dose on days -3 & -2,, through a cvc. Melphalan doseadjustments are made for age & CRCL,. Pts with, CRCL,> 51ml/min receive melphalan at 200mg/m2. Pts with CRCL < 51ml/min, (to be evaluated within 2 weeks of SCT) will receive 140mg/m2. Pts > 70 years, old receive 140mg/m2 also. Each SCT in a tandem SCT is a clinically discrete, event & these rules of dose adjustment apply to each SCT. It is possible,, that pts will get different doses of melphalan in tandem SCT
lenalidomide and dexamethasone (drug) — also listed as: In the initial 4 cycles of therapy, pts will receive oral lenalidomide at the, starting dose of 25mg on days 1-21 every 28 days (one cycle) with dose, adjustments for creatinine clearance and dose reductions. Pts will receive, low-dose oral dexamethasone at 40mg weekly on days 1, 8, 15 & 22 of each, 28-day cycle with dose reductions (the weekly dose could be split over 2 days, in the week i.e. 20mg on days 1, 4, 8, 11, 15, 18, 22, & 25 for better, tolerance). For continued Ld, pts will resume Ld at the last dose tolerated, during the initial 4 cycles, with prophylactics & dose reductions as indicated., Lenalidomide will be continued until progression of disease, if as tolerated., Low-dose dexamethasone will be continued for 1 year (from the start of initial, treatment), as tolerated. Dose adjustments will follow guidelines. Pts will, be seen every 3 months by their physician & their disease will be reassessed., Pts will also have a CBC & pregnancy test performed monthly.

Where the study takes place — 7 listed sites

Memoral Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
Site recruitment: Not reported
Memorial Sloan-Kettering Cancer Center @ Suffolk
Commack, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering West Harrison
Harrison, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States
Site recruitment: Not reported
Memoral Sloan Kettering Cancer Center at Phelps
Sleepy Hollow, New York, United States
Site recruitment: Not reported
Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center
Sleepy Hollow, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Success Rate Natural Cycles Versus Modified Natural Cycles in Frozen Embryos

ClinicalTrials.gov · NCT03798886 · Registry updated: 2019-03-13

Condition / research focus: Infertility, Female
Sponsor: Acibadem University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2018-01-01. Completion: 2019-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

natural cycle (other) — also listed as: natural LH surge
modified natural cycle (other) — also listed as: recombinant hcg
embryo transfer (other) — also listed as: frozen embryo transfer

Where the study takes place — 1 listed sites

Acibadem MAA University Atakent Hospital
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →